CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 42 enrolled
Drug / intervention
Pembrolizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02998268
NCT02998268Phase 2Active
CompareCT.gov

Randomized, Multicenter Phase II Study of Pembrolizumab in Combination With Chemotherapy and Chemoradiation in Locally Advanced Esophageal Adenocarcinoma

Weill Medical College of Cornell University·interventional·Posted Dec 20, 2016·Updated Mar 17, 2026

In Brief

A Phase 2 clinical trial evaluating Pembrolizumab, Taxol, and 1 other intervention for Esophageal Adenocarcinoma. Active but no longer recruiting, targeting 42 participants across 4 sites.

Detailed Summary

This is a randomized, multicenter phase II study of pembrolizumab in combination with chemotherapy and chemoradiation in locally advanced esophageal adenocarcinoma to examine the safety and efficacy of the combination of pembrolizumab with chemotherapy and chemoradiation in locally advanced esophageal adenocarcinoma as assessed by 1 year disease free survival rate.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Adenocarcinoma
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2ActiveOverdue
2017201820192020202120222023202420252026
First PostedDec 20, 2016
Enrollment StartMar 7, 2017
Primary CompletionFeb 10, 2021
Study CompletionMar 1, 2026
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 9.5 years ago

Interventions

Pembrolizumabdrug

Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.

Taxoldrug

Taxol is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions.

Carboplatindrug

Carboplatin is a platinum coordination compound that is used as a cancer chemotherapeutic agent. Carboplatin produces predominantly interstrand DNA cross-links rather than DNA -protein cross-links.